Macrogenics (MGNX) Current Deferred Revenue (2012 - 2026)

Macrogenics (MGNX) has reported Current Deferred Revenue for 15 consecutive years, with $68.0 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Current Deferred Revenue rose 335.29% year-over-year to $68.0 million; the TTM figure through Mar 2026 stood at $68.0 million (up 335.29% YoY), while the FY2025 annual figure was $10.9 million, down 33.08% from the prior year.
• Current Deferred Revenue rose to $68.0 million in Q1 2026 per MGNX's latest filing, from $10.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $100.0 million in Q1 2023 and bottomed at $7.1 million in Q3 2022.
• Historically, Current Deferred Revenue has averaged $23.7 million across 5 years, with a median of $16.3 million in 2024.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 626.19% — and 2024, when it slumped 77.16%.
• Macrogenics' Current Deferred Revenue stood at $10.0 million in 2022, then surged by 116.77% to $21.7 million in 2023, then decreased by 24.63% to $16.3 million in 2024, then slumped by 33.08% to $10.9 million in 2025, then soared by 522.59% to $68.0 million in 2026.
• Business Quant data shows MGNX's Current Deferred Revenue at $68.0 million in Q1 2026, $10.9 million in Q4 2025, and $10.3 million in Q3 2025.